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The Journal of Immunology
Injury-Induced Type I IFN Signaling Regulates Inflammatory
Responses in the Central Nervous System
Reza Khorooshi and Trevor Owens
Innate glial response is critical for the induction of inflammatorymediators and recruitment of leukocytes to sites of the injury in the
CNS. We have examined the involvement of type I IFN signaling in the mouse hippocampus following sterile injury (transection of
entorhinal afferents). Type I IFNs signal through a receptor (IFNAR), which involves activation of IFN regulatory factor (IRF)9,
leading to the induction of IFN-stimulated genes including IRF7, that in turn enhances the induction of type I IFN. Axonal
transection induced upregulation of IRF7 and IRF9 in hippocampus. Induction of IRF7 and IRF9mRNAs was IFNAR dependent.
Double-labeling immunofluorescence showed that IRF7 selectively was induced in Mac-1/CD11b+ macrophages/microglia in
hippocampus after axonal transection. IRF7 mRNA was also detected in microglia sorted by flow cytometry. Lack of type I IFN
signaling resulted in increased leukocyte infiltration into the lesion-reactive hippocampus. Axonal lesion-induced CXCL10 gene
expression was abrogated, whereas matrix metalloproteinase 9 mRNAwas elevated in IFNAR-deficient mice. Our findings point to
a role for type I IFN signaling in regulation of CNS response to sterile injury. The Journal of Immunology, 2010, 185: 1258–1264.
I
njury to the CNS induces an innate glial response, in which
microglia and astrocytes become activated. This response is
essential for the induction of cytokines and chemokines,
which initiate a variety of cellular responses including the mi-
gration of peripheral immune cells into the damaged tissue. The
activation of glial cells and the entry of leukocytes may be ben-
eficial for repair and regeneration processes in the damaged CNS
but may also exacerbate neurodegeneration (1, 2).
The molecular basis for glial activation is poorly understood. The
initial glial response involves TLR signaling, which can induce
proinflammatory cytokines (3, 4), among them type I IFNs. Type I
IFNs (IFN-a and IFN-b) play a critical role in the innate immune
response against viral infection (5). The signaling pathway for
both IFN-a and IFN-b involves a common cell surface receptor,
IFNAR. IFNAR is associated with STAT1 and STAT2, which
together with IFN regulatory factor (IRF)9 form a complex that
binds to IFN-stimulated response element in promotor regions and
stimulates type I IFN-dependent gene transcription including IRF7
(6, 7). IRF7 has been described as a master regulator of type I IFN
signaling (8, 9).
Type I IFN signaling is normally associated with antiviral im-
mune responses (10). IFN-b is also used in the treatment of
multiple sclerosis, and mice with defective type I IFN signaling
develop more severe experimental autoimmune encephalomyelitis
(EAE) (11, 12), indicating the involvement of type I IFN signaling
in the regulation of CNS inflammation. Involvement of type I IFN
in a noninfectious injury-induced glial response has not been
studied. A well-established and widely used model to study the
glial response after brain injury is an entorhinal axonal lesion. The
transection of projections from entorhinal cortex to the hippocam-
pus leads to anterograde axonal degeneration and loss of synapses
in the outer molecular layer of the dentate gyrus, followed by glial
activation, leukocyte infiltration, and sprouting (13–20). Involve-
ment of TLR signaling as well as cytokines (TNF-a and IL-1b)
and chemokines (CCL2 and CXCL10) in glial response and re-
cruitment of leukocytes in the lesion-reactive hippocampus have
been described previously (15, 17, 21, 22). We previously de-
scribed glial upregulation of STAT1 and STAT2 (21), which sug-
gested the involvement of type I IFN signaling.
The aim of this study was to examine the involvement and
functional significance of type I IFN signaling in lesion-induced
glial responses. We show that sterile axonal lesion induces IRF7
and IRF9 gene expression and that this is IFNAR dependent. Im-
munohistochemical staining and flow cytometry localized IRF7 to
Mac1/CD11b+ macrophages/microglia in lesion-reactive hippo-
campus at 1 d postlesion. Leukocyte infiltration was increased in
IFNAR-deficient mice. Unlike wild-type (WT) mice, axonal lesion
did not induce an increase in CXCL10, but it induced an increase in
matrix metalloproteinase (MMP)9 gene expression in IFNAR-
knockout (KO) mice. These findings identify a role for type I
IFN in regulating innate responses to CNS injury.
Materials and Methods
Animals
Adult female mice deficient in STAT1 (STAT1-KO) 129s6/SvEv background
(23) were purchased from Taconic Farms (Germantown, NY), IFNAR-KO
on 129s6/SvEv background were purchased from B&K Universal Limited
(Hull, U.K.), IRF7-KO on C57BL/6 background were purchased from Riken
BRC (Tsukuba, Japan) with agreement from Dr. T. Taniguchi (Department of
Immunology, University of Tokyo, Tokyo, Japan) (9), and IFNAR-KO on
C57BL/6 background (11) were provided by Dr. M. Prinz (Department of
Neuropathology, University of Freiburg, Germany). WT mice (C57BL/6
and129s6/SvEv) were purchased from Taconic (Taconic Europe, Ry, Den-
mark). These experiments were conducted according to the guidelines of
the National Danish Animal Research Committee.
Entorhinal cortex lesioning and tissue preparation
Under anesthesia, adult female (18–20 g) mice were placed in a Kopf
stereotactic apparatus (Kopf Instruments, Tujunga, CA). The entorhino-
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dentate perforant path projection was transected as described previously
(21).
For immunohistochemical analysis, mice were perfused transcardially
with PBS, followed by 4% paraformaldehyde (Sigma-Aldrich, Broendby,
Denmark) in PBS. The brains were removed and postfixed in PBS contain-
ing 4% paraformaldehyde for 2 h on ice, then immersed in 30% sucrose in
PBS overnight at 4˚C, frozen with CO2-snow, and stored at 220˚C until
sectioning. For flow cytometry and quantitative real-time RT-PCR analysis,
mice were perfused transcardially with PBS, and brains were removed
aseptically.
Single- and dual-labeling immunohistochemistry
Immunohistochemical staining was performed as described previously (21).
In brief, after blocking endogenous peroxidases, the sections were incubated
overnight with rabbit anti-IRF7 Ab (SC-9083; Santa Cruz Biotechnology,
Santa Cruz, CA), rat anti-mouseMac-1/CD11b (MCA711; Serotec, Oxford,
U.K.) (to identify microglia/macrophages), or rabbit anti-GFAP (Z0334;
DakoCytomation, Glostrup, Denmark) (to identify astrocytes), and in the
following day, the sections were incubated with secondary biotinylated Ab
(Amersham Biosciences, Little Chalfont, U.K.). The sections were finally
incubated with streptavidin-HRP (P0397; DakoCytomation) and developed
with 0.5 mg/ml diaminobenzidine (Sigma-Aldrich).
For dual-labeling immunofluorescence, sections were incubated with
rabbit anti-IRF7 and with rat anti-mouse Mac-1/CD11b or monoclonal
mouse anti–GFAP-cy3–conjugated Abs (C9205; Sigma-Aldrich), followed
by incubation with fluorescent secondary Abs, Alexa 488-labeled goat anti-
rabbit (A11034; Invitrogen, Taastrup, Denmark) andAlexa 568-labeled goat
anti-rat (A11077; Invitrogen), as described previously (21). Images were
acquired using either an Olympus BX51 microscope (Olympus, Ballerup,
Denmark) connected to an Olympus DP71 digital camera and a Confocal
laser scanning fluorescence microscope (Olympus FV1000; Olympus,
Hamburg, Germany). Images were combined using Adobe Photoshop CS
version 8.0 to visualize double-labeled cells. To verify Ab specificity, con-
trol sections were treated without primary Ab or with isotype-matched
primary Abs. Control sections displayed no staining comparable with that
seen with primary Abs (data not shown).
Western blotting
Western blot analysis was performed as described previously (21). Both
contralateral and ipsilateral hippocampi were isolated from PBS-perfused
mice and lysed in lysis buffer. Cell lysate was mixed with sample buffer,
denatured by boiling, and separated by electrophoresis in an 8–10% poly-
acrylamide gel. The separated proteins were transferred to a nitrocellulose
membrane (Bio-Rad, Hercules, CA). The membranes were blocked for 1 h
at room temperature in 5% nonfat dry milk in PBS containing 0.1% Tween
20 (PBST). The membranes were then incubated with rabbit anti-IRF7
and/or rabbit anti-actin (A5060; Sigma-Aldrich) Abs at 4˚C overnight.
After washing in PBST, the membranes were incubated with goat anti-
rabbit IgG HRP conjugate (Sigma-Aldrich) for 1 h at room temperature.
Staining was detected using chemical luminescence methodology (GE
Healthcare U.K., Amersham Place, U.K.). The intensities of IRF7 and
actin were calculated using an image analyzing system (ImageJ; National
Institutes of Health, Bethesda, MD). The relative levels of IRF7 were nor-
malized against the levels of actin, and values from lesion-reactive hippo-
campi were divided by the values from contralateral to calculate the fold
induction of IRF7.
Fluoro-Jade staining
Fluoro-Jade (FJ) is used as a marker to identify degenerating neuronal tissue
(24). To examine whether lack of IFNAR signaling may affect FJ staining
in the outer molecular layer of dentate gyrus, brain sections were stained
with FJ (Histo-Chem, Jefferson, AK). Sections were immersed in 100%
ethanol for 3 min in 70% ethanol for 1 min and rinsed in H2O for 1 min
before being incubated for 15 min in 0.06% KMnO4. Thereafter, tissue was
rinsed for 1 min in H2O and stained for 45 min in 0.001% FJ solution
diluted in 0.1% acetic acid. Sections were then rinsed in distilled water,
air-dried, dipped in xylene, coverslipped, and mounted with Depex.
Quantitative real-time PCR
As previously described (21), RNA was isolated from the contralateral,
ipsilateral, and unmanipulated hippocampi and converted to cDNA.
Quantitative real-time PCR was performed using an ABI Prism 7300 Se-
quence Detection System (Applied Biosystems, Foster City, CA) (21). 18S
rRNA was measured as a control and used to normalize gene expression
(Applied Biosystems). Primer and probe sequences were as follows: CCL2
(forward, TCT GGG CCT GCT GTT CAC A; reverse, CCTACTCATT-
GGGATCATCTTGCT; probe, FAM-CTCAGCCAGATGCAGTT-MGB);
TNF-a (forward, CCAAATGGCCTC CCTCTCAT; reverse, TCCTCCAC-
TTGGTGGTTTGC; probe, FAM-CTCACACTCAGATCAT-MGB); CXCL10
(forward, GCCGTCATT TTCTGCCTCAT; reverse, GGCCCGTCATCGATA
TGG; probe, FAM-GGACTCAAGGGATCC-MGB); IL-1b (forward, CTTG-
GGCCTCAAAGG AAAGAA; reverse, AAGACAAACCGTTTTTCCATCT-
TC; probe, FAM-AGC TGG AGAGTGTGGAT-MGB); IRF7 (forward, CAC-
CCCCATCTTCGACTTCA; reverse, CCAAAACCCAGGTAGATGGTGTA;
probe, FAM-CACTTTCTTCCGAGAACT-MGB); IRF9 (forward, ACAACT-
GAGGCCACCATTAGAGA; reverse, CACCACTCGGCCACCATAG; probe,
FAM-TGAACTCAGACTACTCGCT-MGB); IRF3 (forward, CACCCCAA-
GAAAATCCACTGA; reverse, AGGCGGTCACCTCGAACTC; probe, FAM-
TAGCTGAGGAACAATG-MGB); and MMP9 (forward, CGAACTTCGACA-
CTGACAAGAAGT; reverse, GCACGCTGGAATGATCTAAGC; probe, FAM-
TCTGTCCAGACCAAGGGTACAGCCTGTTC-MGB).
Flow cytometry
To measure leukocyte entry in response to axonal injury, hippocampi were
homogenized and incubated with blocking solution to block nonspecific
staining as described previously (21). Cells were then stained with rat anti-
mouse CD45-conjugated PE, rat anti-CD11b–conjugated PerCP, and hamster
anti-mouse TCR-b–conjugated APC Abs (BD Biosciences, Erembodegem,
Belgium) to detect microglia/macrophages or T cells, respectively (15, 17).
Data were collected on a FACSCalibur (BD Biosciences, San Jose, CA) and
analyzed using FlowJo software (Tree Star, Ashland, OR) (21).
To sort microglia and macrophages, hippocampi were pooled from six
mice, and a similar experiment was performed as described above with
few modifications. Homogenates were enriched for mononuclear cells by
centrifugation through 33% isotonic Percoll prior to blocking the non-
specific staining. After staining with respective Abs, cells were sorted by
a FACSVantage/Diva Sorting Flow Cytometer (BD Biosciences). Total
RNAwas extracted using TRIzol reagent as previously described (21) and
converted to cDNA, and quantitative real-time PCR was performed as
described above. DCT values for IRF7 gene expression were then calcu-
lated. DCT is the difference in CT between IRF7 gene and the internal
reference control gene, 18S rRNA.
Data analysis
Results were analyzed by two-tailed paired/unpaired t test or one-way
ANOVAwith Bonferroni’s posttest using GraphPad Prism software (Graph-
Pad Software, San Diego, CA). A value of p , 0.05 was considered to be
statistically significant. Data are presented as mean 6 SEM.
Results
Lesion-induced IRF7 gene expression was STAT1 and IFNAR
dependent
IRF7 mRNA was constitutively expressed at low levels in un-
manipulated hippocampi from WT, IFNAR-KO, and STAT1-KO
mice (data not shown). Levels of IRF7 increased significantly in
lesion-reactive hippocampi of WT mice at 1, 3, and 5 d (Fig. 1A).
In contrast, axonal lesion did not induce a significant increase in IRF7
gene expression in IFNAR-KO and STAT1-KO mice (Fig. 1A).
Whether or not mice were on 129s6/SvEv (Fig. 1A) or C57BL/6
(Fig. 1B) background had no effect on these events.
Like IRF7, IRF9 mRNA was constitutively expressed at low
levels in unmanipulated hippocampi from both WT and
IFNAR-KO mice (data not shown). IRF9 mRNA levels increased
in the lesion-reactive hippocampi at 1 d postlesion, and this was
also IFNAR dependent (Fig.1C).
In addition to IRF7 and IRF9, we also examined IRF3 gene
expression. IRF3 is involved in the early induction of type I IFNs
in antiviral immune response (25). IRF3 was constitutively ex-
pressed in unmanpulated hippocampi in both WT and IFNAR-
KO mice. Unlike IRF7 and IRF9, there was no induction of
IRF3 at 1 d after lesion (data not shown).
IRF7 was expressed by microglia/macrophages in the outer
molecular layer of dentate gyrus
We next examined IRF7 distribution and cellular localization in the
denervated outer molecular layer of the dentate gyrus at 1 d post-
lesion. IRF7 immunoreactivity was not evident in unmanipulated
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hippocampus and in corresponding regions of the contralateral
hippocampus in lesioned animals (Fig. 2A). However, axonal lesion-
induced increased IRF7 immunostaining in the outer molecular
layer in dispersed cells that had morphologic features resembling
activated microglia or macrophages (Fig. 2B, 2C). Double labeling
with Mac-1/CD11b and GFAP showed that IRF7 colocalized with
Mac-1/CD11b (Fig. 2D–G) and not with GFAP (Fig. 2H–K), in-
dicating expression in microglia/macrophages.
IRF7 protein was also detected by Western blotting (data not
shown). We identified relevant bands on the basis of their absence
from Western blots of hippocampal lysates from IRF7-KO mice;
this verified the specificity of IRF7 Ab (data not shown). The level
of IRF7 protein did not increase at 1 d postlesion in lesion-reactive
hippocampi compared with contralateral from either WT or IFNAR-
KO mice (data not shown).
IRF7 gene expression in sorted CD45dimCD11b+ microglia
The expression of IRF7 protein in Mac-1/CD11b microglia/
macrophages was confirmed by analysis of IRF7 gene expression
in microglia sorted by flow cytometry (Fig. 3). IRF7 gene expres-
sion could be detected in sorted CD45dimCD11b+ microglia at 1 d
postaxonal lesion (Fig. 3). DCT values for IRF7 gene expression
in CD45dimCd11b+ microglia were ∼16 (Fig. 3B). Because of the
limited number of CD45high CD11b macrophages sorted by flow
cytometry from hippocampi, we were not able to detect IRF7 gene
expression in macrophages (Fig. 3).
Lesion-induced leukocyte infiltration was increased in
IFNAR-KO mice
The upregulation of downstream components of type I IFN sig-
naling indicates involvement in axonal lesion-induced glial response.
Low levels of type I IFN gene expression could be detected in hip-
pocampal samples by quantitative real-time PCR (data not shown).
However, expression was difficult to detect, and it was not possible to
reliably determine whether axonal-lesion influenced type I IFN in-
duction, consistent with findings by Ousman et al. (10), in which the
levels of type I IFN within the CNS were at the limit of detection
even after several days postvirus infection.
To examine the functional significance of type I signaling in this
model, leukocyte recruitment to the lesion-reactive hippocampi
was analyzed by flow cytometry, measuring the proportion of
CD45high cells (Fig. 4A). Proportions of blood-derived leukocytes
were similarly low in unmanipulated hippocampi from WT and
IFNAR-KO mice, regardless of strain background. The proportion
of CD45 high cells was significantly increased in lesion-reactive
hippocampi of both WT and IFNAR-KO mice compared with the
contralateral hippocampus of each mouse, regardless of whether
WT and IFNAR-KO mice were on C57BL/6 (data not shown) or
129s6/SvEv (Fig. 4B) backgrounds. However, the proportions of
FIGURE 1. Injury-induced increase
in IRF7 and IRF9 gene expression was
IFNAR and STAT1 dependent. A, IRF7
mRNA increased significantly in lesion-
reactive hippocampi of 129s6/SvEv WT
but not in IFNAR-KO and STAT1-KO
mice at 1, 3, and 5 d postaxonal lesion.
B, IRF7mRNA increased significantly in
lesion-reactive hippocampi of C57BL/6
WT but not in IFNAR-KO mice on
C57BL/6 background. C, IRF9 gene ex-
pression was increased in lesion-reactive
hippocampi ofWT but not in IFNAR-KO
mice at 1 d postlesion. Groups ofmatched
contralateral and lesion-reactive hippo-
campiwere analyzed by two-tailed paired
Student t test. pStatistically significant
differences versus contralateral as fol-
lows: A, 1 day postlesion (dpl), p =
0.009; 3 dpl, p = 0.031; 5 dpl, p =
0.031; B, WT, p = 0.0039; and C, WT,
p = 0.001. Error bars represent SEM.
C, contralateral; L, lesion-reactive hippo-
campi.
FIGURE 2. IRF7 immunoreactivity increased in lesion-reactive hippo-
campi at 1 d postlesion. A, IRF7 immunoreactivity was not evident in
contralateral hippocampus. B, Axonal lesion-induced increase IRF7 immu-
noreactivity was detected in a few cells (arrow) dispersed within denervated
outer molecular layer. C, Higher magnification of IRF7 immunoreactive
cells (arrow) in B. D–K, Double labeling of IRF7 with Mac-1/CD11b (D–
G) and GFAP (H–K) Abs showed that IRF7 immunoreactivity colocalized
with Mac-1/CD11b-immunoreactive cells (D–G, arrow) but not with GFAP-
immunostained cells (H–K). C, contralateral; L, lesion-reactive hippocampi.
Original magnification320 (A, B, H–K), 340 (C, D–G). Scale bars, 25 mm
(A, B); 10 mm (C); 50 mm (D–G); and 20 mm (H–K).
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infiltrating CD45high cells were significantly higher in IFNAR-KO
than in WT mice (Fig. 4B) at 1 d. Lesion-induced increase in
leukocyte infiltration in IFNAR-KO mice compared with WT
was transient and was not seen at 3 and 5 d postlesion (Fig.
4B), although the proportion of infiltrating CD45high cells were
increased by lesion in both WT and IFNAR-KO mice at these time
(Fig. 4B). The fold increase in leukocyte infiltration in lesion-
reactive versus contralateral hippocampus at 1 d in IFNAR-KO
mice was 3-fold higher than WT (Fig. 4C).
Leukocyte infiltration to lesion-reactive hippocampus includes
both T cells and macrophages (15, 17). To ask whether IFNAR
deficiency differentially affected T cell and macrophage infiltra-
tion, we counted proportions of CD11b+ and TCR-b+CD45high
cells. Whereas the proportion of macrophages (CD45highCD11b+)
doubled in lesioned IFNAR-deficient hippocampus compared with
WT, the lesion-induced increase in T cells (CD45highTCR-b+) was
not affected by IFNAR deficiency (data not shown). There was no
significant difference between the proportions of CD45dimCD11b+
microglia in lesion-reactive hippocampi of WT and IFNAR-KO
mice (data not shown).
Lesion-induced CXCL10 and MMP9 gene expression were
IFNAR regulated
Our findings indicate that IFNAR deficiency leads to increased
leukocyte infiltration in lesion-reactive hippocampus. The involve-
ment of cytokines (including TNF-a and IL-1b) and chemokines
(including CCL2 and CXCL10) in leukocyte entry to CNS has been
shown previously (21, 26, 27). In addition, MMPs are known to
degrade extracellular matrix and to facilitate leukocyte infiltration
to the CNS (28). Interestingly, type I IFN signaling regulatesMMP9
expression (29). We next examined whether increased infiltration
correlated with changes in expression of lesion-induced CCL2,
CXCL10, TNF-a, IL-1b, and MMP9. As previously shown (17,
21), axonal injury induced upregulation of CXCL10 (Fig. 5A),
CCL2 (Fig. 5B), TNF-a (Fig. 5C), and IL-1b (Fig. 5D) in WT
mice. In IFNAR-KO mice, axonal injury also induced a significant
increase in CCL2 (Fig. 5B), TNF-a (Fig. 5C), and IL-1b (Fig. 5D)
but not in CXCL10 gene expression (Fig. 5A). Unlike WT mice,
MMP9 gene expression increased significantly in lesion-reactive hip-
pocampi from IFNAR-KO mice (Fig. 5E).
FJ and glial staining in response to axonal lesion
To examine whether lack of type I IFN signaling may influence
axonal degeneration and glial response in the outer molecular layer
of dentate gyrus, we performed FJ, Mac-1/CD11b, and GFAP stain-
ing on brain sections fromWTand IFNAR-KO mice at 1, 3, and 5 d.
FJ staining was present at a very low level in the outer molecular
layer of dentate gyrus from both WT and IFNAR-KO at 1 d post-
axonal lesion (Fig. 6A, 6B). The level of FJ staining increased in
the outer molecular layer of dentate gyrus from both WT and
IFNAR-KO at 3 (insets in Fig. 6A, 6B) and 5 d (data not shown)
postaxonal lesion. The comparison of WT with IFNAR-KO mice
showed that the lack of type I IFN signaling had no effect on FJ-
staining pattern in the outer molecular layer of dentate gyrus at 1
(Fig. 6A, 6B), 3 (insets in Fig. 6A, 6B), and 5 d (data not shown)
postlesion.
As expected, lesion caused an increase of both GFAP (Fig. 6C,
6D, arrow) and Mac-1/Cd11b (Fig. 6E, 6F, arrow) immunoreac-
tivity in the outer molecular layer of dentate gyrus in WT at 1 (Fig.
6C–F), 3 (data not shown), and 5 d (data not shown). However, no
differences in GFAP and Mac-1/Cd11b immunostaining were
found between WT and IFNAR-deficient mice (Fig. 6C–F).
Discussion
Our findings show the involvement of type I IFN signaling in re-
sponse to sterile injury in the CNS. Type I IFN signaling in the CNS
is normally associated with antiviral immune responses (10, 30).
FIGURE 3. IRF7 gene expression in FACS-sorted CD45dimCd11b+
microglia. A, An example of a representative FACS profile showing the
distribution of CD45highCD11b+ (macrophages) and CD45dimCd11b+
(microglia) cell populations at 1 d postaxonal lesion. B, IRF7 gene expres-
sion in CD45dimCd11b+. DCT values for IRF7 gene expression. IRF7 gene
expression could be detected in CD45dimCd11b+ (microglia) but not in
CD45highCD11b+ (macrophages) at 1 d postaxonal lesion. C, contralateral;
L, lesion-reactive hippocampi.
FIGURE 4. Axonal injury-induced increased leukocyte infiltration was
higher in IFNAR-KO mice compared with WT mice. A, Representative
FACS profiles for CD45 and TCR-b staining of lesion-reactive hippocampi
from WT 129s6/SvEv (left panel) and IFNAR-KO mice on 129s6/SvEv
background (right panel) at 1 d after axonal lesion. B, Lesion-induced
increase in proportions of infiltrating CD45high cells was significantly
higher in the hippocampi of 129s6/SvEv IFNAR-KO compared with WT
at 1 d postlesion. However, at 0, 3, and 5 d postaxonal lesion, there was no
significant difference in proportions of infiltrating CD45high cells in lesion-
reactive hippocampi of WT compared with IFNAR-KO mice. Data were
analyzed by two-tailed unpaired Student t test. pp = 0.026, day 1; statis-
tically significant differences between lesion-reactive and WT hippocampi.
C, The increase in leukocyte infiltration in lesion-reactive relative to con-
tralateral hippocampus at 1 d in IFNAR-KO mice was 3-fold higher than
WT. Data were analyzed by two-tailed unpaired Student t test; p = 0.0085.
Error bars represent SEM. C, contralateral; L, lesion-reactive hippocampi.
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Type I IFNs exert a wide range of effects on inflammatory processes
in the CNS during infection and in EAE, in both of which pathogen-
associated signals may play a role. The functional significance of
type I IFN in sterile injury-induced response in the CNS is therefore
of interest. Similar to findings in viral infection models (10, 30), the
expression of IRF7 and IRF9 gene increased following axonal le-
sion, and this increase was IFNAR dependent (10). Other studies
have shown a role for type I IFN in regulating leukocyte infiltration
to the CNS in EAE models (11, 12, 31), and we have shown
a similar effect in response to sterile injury. Our results support
an innate signaling role for type I IFN in the CNS.
IRF7 and IRF9 belong to a family of transcription factors with
diverse functions including host defense, regulation of cell growth,
apoptosis, and immune cell development. However, mice deficient
in IRF7 and IRF9 develop normally and have no obvious differ-
ences in size and behavior compared with WT littermates (9, 32).
Most importantly, these two reports emphasize the essential role
of IRF7 and IRF9 in the regulation of type I IFN signaling and
antiviral defense. The CNS is susceptible to infection, and con-
stitutive expression of IRF7 and IRF9 may therefore be necessary
for initiation of type I IFN response to infection. In the current
study, we showed CNS upregulation of IRF7 and IRF9 in response
to injury, which suggest their involvement in noninfectious re-
sponses as well.
IRF7 gene expression is specifically of interest, because it pos-
itively regulates the induction of type I IFN, which in turn regu-
lates IRF7 induction. The cellular expression of IRF7 may there-
fore be indicative of the source of type I IFN. We have been able
to show induction of IFN-a and IFN-b by RT-PCR in lesion-
reactive hippocampus, but this has been difficult to reproduce,
and we have been unable to localize the cellular source of IFN
I. This is probably due to a combination of low expression level
and that current methods are not sensitive enough to detect the
differences in type I IFN induced by injury in this model. Identi-
fication and localization of type I IFN in the CNS is of interest,
particularly in response to viral infection. To our knowledge, only
two studies have identified the source of type I IFN in the CNS.
Delhaye et al. (30) identified that neurons produced IFN-a in
response to infection, and Teige et al. (12) found that during
EAE, both infiltrating cells and cells with the morphology of
microglia expressed IFN-b. Otherwise, surrogate markers of
downstream signaling associated with type I IFN signaling have
been used to identify type I IFN-producing cells within the CNS
(10, 30).
Our results pointed to upregulation of IRF7 in Mac-1/CD11b+
microglia/macrophages, although absence of IRF7 immunoreac-
tivity in other cell types does not exclude their ability to produce
type I IFN. IRF7 protein expression could be detected in un-
manipulated hippocampal samples as well as in contralateral and
lesion-reactive hippocampi. Furthermore, both PCR and Western
blot analysis showed that the level of IRF7 protein expression was
higher in WT mice compared with IFNAR-KO mice, although
not significantly. The immunostaining of sections with IRF7 Ab
showed increased but dispersed IRF7+ cells in the outer molecular
layer of dentate gyrus in response to axonal lesion. This increased
immunoreactivity was not detected by Western blotting, which
probably reflects lower sensitivity of Western blotting of whole
hippocampal isolates versus immunohistochemistry, by which
IRF7 expression could be detected even in very few cells.
We showed that the axonal lesion resulted in increased ex-
pression of IRF7 gene, and this increase was IFNAR dependent.
IFNAR-dependent induction of IRF7 has also been shown in
FIGURE 5. Lesion-induced CXCL10 and MMP9 gene expression was
IFNAR dependent. Whereas CXCL10 gene expression (A) did not increase
significantly in lesion-reactive hippocampi of IFNAR-deficient mice,
CCL2 (B), TNF-a (C), and IL-1b (D) were significantly increased in
lesion-reactive hippocampi of both WT and IFNAR-KO mice at 1 d post-
axonal lesion. (E) In contrast to WT, lesion induced a significant increase
in MMP9 gene expression in IFNAR-deficient mice at 1 day post axonal
lesion. Data were analyzed using one-way ANOVA with Bonferroni’s
posthoc analysis. Error bars represent SEM. Statistically significant differ-
ences versus contralateral. pp , 0.05; ppp , 0.01; pppp , 0.001. †Not
significantly different between contralaterals for each message. C, contra-
lateral; L, lesion-reactive hippocampi.
FIGURE 6. FJ, GFAP, and Mac-1/CD11b staining in the outer molecular
layer of dentate gyrus in response to axonal lesion. A and B, Images showing
FJ staining in lesion-reactive hippocampi of WT versus IFNAR-KO at 1 d. FJ
staining was present at very low level in the outer molecular layer of dentate
gyrus at 1 d postaxonal lesion. Levels of FJ staining increased in the outer
molecular layer of dentate gyrus at 3 d after axonal lesion of bothWT (inset in
A) and IFNAR-KO (inset in B). No differences in FJ staining were observed
between IFNAR-KO and WT mice. Axonal lesion caused an increase GFAP
(C,D, arrows) andMac-1/Cd11b immunoreactivity (E, F, arrows) in the outer
molecular layer of dentate gyrus. However, there were no differences in
GFAP and Mac-1/Cd11b immunoreactivity between IFNAR-KO and WT
mice. DG, dentate gyrus; OML, outer molecular layer. Original magnification
310 (A, B, insets),340 (C–F). Scale bars, 20 mm.
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response to toxin-induced demyelination, although there appeared
to be no role for type I IFN signaling, and the cell source was not
identified (33). In virally infected brain, IRF7 gene expression was
detected in astrocytes, microglia, neurons, and infiltrating CD3+
T cells (10). Another study showed that viral infection induced
upregulation of IRF7 and type I IFN in neurons as well as in Mac-
1/CD11b+ microglia/macrophages (30). It is also evident that all
cells in the CNS can respond to type I IFN (30, 34–36). IRF7
alone or together with IRF3 can induce transcription of type I IFN
(8, 25). Hippocampal IRF3 gene expression was unaltered in re-
sponse to axonal lesion in both WT and IFNAR-KO after 1 d,
suggesting that IRF3 may not be involved in this case. Similarly,
viral infection in the CNS did not induce changes in IRF3 gene
expression, even after several days (10).
Our findings extend to the sterile injury response observation of
type I IFN regulation of leukocyte entry to the CNS. The proportion
of CD45highCD11b+ macrophages but not of CD45highTCR-b+
T cells doubled in IFNAR-KO in comparison with WT animals
at 1 d postaxonal lesion. Analogous effects of type I IFN signaling
on infiltration of macrophages to the CNS have been demonstrated in
EAE (11, 12, 31). Increased clinical scores of EAE in IFNAR-KO
micewere associatedwith elevated number ofMAC-3+macrophages
(11), and treatment with IFN-b reduced both the clinical scores and
the number of ED1+ macrophages in rats (31). In addition, it was
reported that the CNS of IFN-b–KO mice contained more activated
macrophages than inWTmice (12). Lack of type I IFN signaling had
no effect on T cell infiltration in the two of these studies, in which
it was examined (11, 12).
Unlike in WT mice, CXCL10 gene expression was not elevated
in lesioned IFNAR-KO mice. In contrast, CCL2, TNF-a, and
IL-1b were similarly upregulated in both IFNAR-KO and WT
mice. This contrasts with findings in EAE, in which elevated
macrophage infiltration correlated with increased levels of TNF-a,
CCL2, and CXCL10 expression in IFNAR- and IFN-b–KO com-
pared with WT mice (11, 12). As shown by others and ourselves in
entorhinal cortex lesion and other models of brain injury, glial
cells represent a major source for many of these mediators. Pre-
vious studies identified microglia and astrocytes as a prominent
source of CCL2 (17). IL-1b and TNF are also glial derived (37,
38), and we must assume that the leukocyte contribution was not
significant in this case. The differences in effect on CXCL10 may
reflect involvement of adjuvant in the EAE model or other dif-
ferences between these systems. It has been demonstrated that an
IFN-stimulated response element is contained in the CXCL10 pro-
moter (39, 40). Type I IFN is capable of stimulating CXCL10
production by hepatocytes in vitro, and ischemia/reperfusion-
triggered intrahepatic CXCL10 expression was diminished in
IFNAR-KO mice (41). The induction of CXCL10 has been used
as biomarker to measure type I IFN activity (42). Our study sug-
gests that type I IFN signaling normally either allows or directly
stimulates CXCL10 production in the CNS in response to axonal
injury. Our findings further suggest that type I IFN signaling may
regulate leukocyte entry through this or other mechanisms involv-
ing disruption of blood-brain barrier (29). MMP9 is involved in
degradation of extracellular matrix and facilitating the recruitment
of leukocytes (28, 43). In the CNS, both astrocytes and microglia
express MMP9 (28), and it is also expressed by infiltrating macro-
phages (44). It has been shown that type I IFN inhibits MMP9
expression in astrocytes and microglia and reduces leukocyte in-
filtration to the CNS (29, 43, 45–47). We find that in the absence
of type I IFN signaling, MMP9 was significantly increased. This
could both result from and contribute to the increased leukocyte
entry into the hippocampus of IFNAR-deficient mice in response
to axonal lesion.
These findings of innate expression and response to type I IFN
in the CNS likely have relevance to understanding the effectiveness
of IFN-b as a therapeutic for multiple sclerosis. Innate signaling
pathways in the CNS offer potential new targets for therapy for
neuroinflammatory diseases.
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